• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormones
(American Heart Association) Patients with breast and prostate cancers who are treated with hormonal therapies have an increased risk of heart attack and/or stroke as they age.The increased likelihood of a heart attack or stroke is greater in patients who already have two or more cardiovascular risk factors such as high blood pressure, high cholesterol, obesity, smoking or a family history of heart disease or stroke.The longer the duration of hormonal therapy, the higher the risk of cardiovascular disease.
Source: EurekAlert! - Medicine and Health - April 26, 2021 Category: International Medicine & Public Health Source Type: news

Randomized Trial Evaluation of Benefits and Risks of Menopausal Hormone Therapy Among Women Aged 50-59.
Abstract The health benefits and risks of menopausal hormone therapy among women aged 50-59 years are examined in the Women's Health Initiative randomized, placebo-controlled trials using long-term follow-up data and a parsimonious statistical model that leverages data from older participants to increase precision. These trials enrolled 27,347 healthy post-menopausal women aged 50-79 at 40 U.S. clinical centers during 1993-1998, including 10,739 post-hysterectomy participants in a trial of conjugated equine estrogens, and 16,608 participants with uterus in the trial of these estrogens plus medroxyprogesterone acet...
Source: Am J Epidemiol - October 7, 2020 Category: Epidemiology Authors: Prentice RL, Aragaki AK, Chlebowski RT, Rossouw JE, Anderson GL, Stefanick ML, Wactawski-Wende J, Kuller LH, Wallace R, Johnson KC, Shadyab AH, Gass M, Manson JAE Tags: Am J Epidemiol Source Type: research

The Women's Health Initiative Estrogen-alone Trial had differential disease and medical expenditure consequences across age groups
Conclusion: The decline in ET utilization had differential disease and expenditure consequences by age groups in the United States. These results are limited by the lack of inclusion of vasomotor symptom benefit and costs of alternative medications for these symptoms in the analysis.
Source: Menopause - May 29, 2020 Category: OBGYN Tags: Original Studies Source Type: research

Cardiovascular Programming During and After Diabetic Pregnancy: Role of Placental Dysfunction and IUGR
This study demonstrated that the incidence of ischemic heart disease and death were three times higher among men with low birth weight compared to men with high birth weight (5). Epidemiological investigations of adults born at the time of the Dutch famine between 1944 and 1945 revealed an association between maternal starvation and a low infant birth weight with a high incidence of hypertension and coronary heart disease in these adults (23). Furthermore, Painter et al. reported the incidence of early onset coronary heart disease among persons conceived during the Dutch famine (24). In that regard, Barker's findin...
Source: Frontiers in Endocrinology - April 8, 2019 Category: Endocrinology Source Type: research

In assessing risk of hormone therapy for menopause, dose — not form — matters
FINDINGSWhen it comes to assessing the risk of estrogen therapy for menopause, how the therapy is delivered — taking a pill versus wearing a patch on one’s skin — doesn’t affect risk or benefit, researchers at UCLA and elsewhere have found. But with the commonly used conjugated equine estrogen, plus progestogen, the dosage does. Higher doses, especially over time, are associated with greater risk of problems, including heart disease and some types of cancer, especially among obese women.BACKGROUNDThe Women ’s Health Initiative established the potential of estrogen therapy to increase or decrease the risk of strok...
Source: UCLA Newsroom: Health Sciences - July 27, 2017 Category: Universities & Medical Training Source Type: news

Does coffee make you live longer?
Conclusion This study, conducted on a large number of people across Europe, was backed up by similar findings in the US. It appears to show some association between people who drink higher amounts of coffee and a reduced risk of death. But the "potentially beneficial clinical implications" need to be considered carefully for a number of reasons: Although the analyses were adjusted for some confounding variables, there may be a number of other factors that differ between the groups that account for the differences in death, such as socioeconomic status, family history, other medical conditions, and use of medic...
Source: NHS News Feed - July 12, 2017 Category: Consumer Health News Tags: Food/diet Source Type: news

Luteolin: How To Reduce Breast Cancer Risk
More than 100 women die of breast cancer in the U.S. every day. It's the second leading cause of cancer deaths in American women. But in my opinion, many of those women really die of a tragic medical error. Let me explain… Millions of women in the U.S. have taken Big Pharma's hormone replacement therapy (HRT). Their doctors prescribe it to try to relieve the symptoms of menopause. Like hot flashes, night sweats, mood swings and weight gain. But what the drug companies try to pass off as hormones are actually synthetic concoctions. They are fake versions of the estrogen and progesterone that your body makes n...
Source: Al Sears, MD Natural Remedies - June 23, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
Authors: Parish SJ, Gillespie JA Abstract This review describes the evolving role of oral hormone therapy (HT) for treating menopausal symptoms and preventing osteoporosis, focusing on conjugated estrogens/bazedoxifene (CE/BZA). Estrogens alleviate hot flushes and prevent bone loss associated with menopause. In nonhysterectomized women, a progestin should be added to estrogens to reduce the risk of endometrial cancer. Use of HT declined since the Women's Health Initiative (WHI) studies showed that HT does not prevent coronary heart disease (CHD) and that conjugated estrogens/medroxyprogesterone acetate increased th...
Source: Postgraduate Medicine - February 1, 2017 Category: Internal Medicine Tags: Postgrad Med Source Type: research

7 Tips To Lower Diabetes Risk in Menopause During the Holidays
By now, most people have been to a holiday party or two. Lots of food, lots of eggnog and other carb laden alcoholic beverages, and lots of grazing all day long on all the boxes of candy friends and business acquaintances sent to us. It's easy to gain the five pounds most people gain during the holidays, and in the process, raise your blood sugar or glucose levels too high. That's your body letting you know you have prediabetes (higher than normal but still below diabetes levels) or diabetes, and unless you take action soon, your body won't like it. Diabetes silently sneaks up on you and if untreated, slowly weakens your ...
Source: Healthy Living - The Huffington Post - December 23, 2016 Category: Consumer Health News Source Type: news

Withdrawal of hormone therapy and increased risk of cardiovascular disease.
Abstract Many menopause specialists follow the principle of prescribing postmenopausal hormone therapy (HT) for the shortest duration needed, in order to decrease the risk of some related serious adverse effects, such as breast cancer. Based on several large studies, it seems, however, that withdrawal of HT may be associated with immediate, though small increased risk of coronary heart disease and stroke. Cessation of HT correlates with increased risk of fractures as well. This information should be relayed to hormone users while discussing the continuation of HT with their health-care provider, but, since the pot...
Source: Climacteric - April 13, 2016 Category: Geriatrics Authors: Pines A Tags: Climacteric Source Type: research

Can HRT in early menopause cut heart disease risk?
ConclusionThis double-blind RCT found that women taking HRT less than six years after the menopause had slower artery wall thickening than those taking a placebo. This represented the main measure of atherosclerosis progression tested; other measures showed no difference, so the results were not as conclusive as they could have been. Women taking HRT 10 or more years after menopause also showed no difference in atherosclerosis progression compared with a placebo, further complicating the picture.An important limitation of this study is the lack of a patient relevant endpoint, such as cardiovascular events or mortality. Pre...
Source: NHS News Feed - April 1, 2016 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news

Women's Health Initiative estrogen plus progestin clinical trial: a study that does not allow establishing relevant clinical risks
Conclusions: The differences in RMST for the outcomes of the WHI study are too small to establish clinical risks related to hormone therapy use.
Source: Menopause - December 1, 2015 Category: OBGYN Tags: Original Articles Source Type: research

Menopausal hormone therapy use in 17 European countries during the last decade
Introduction: The first ‘Women's Health Initiative’ (WHI) randomised controlled trial assessed use of continuous combined menopausal hormone therapy (cc-MHT). It was prematurely stopped because of an increased invasive breast cancer (BC), coronary heart disease (CHD), stroke and pulmonary embolism risk. Consequently, scientific societies recommended use of MHT at the lowest effective dose for the shortest duration. As a result, a sharp decline in MHT use occurred worldwide.
Source: Maturitas - April 21, 2015 Category: Primary Care Authors: Lieveke Ameye, Caroline Antoine, Marianne Paesmans, Evandro de Azambuja, Serge Rozenberg Tags: O44 Source Type: research

Menopausal hormone therapy and ovarian cancer: putting risk into perspective
The wide use of menopausal hormone therapy (MHT) rapidly declined a decade ago after the results of the Women's Health Initiative (WHI) showed that women treated with conjugated equine estrogens plus medroxyprogesterone acetate had an increased risk of breast cancer, coronary heart disease, stroke, and pulmonary embolism [1]. Increased ovarian cancer risk was not reported in the randomized WHI intervention trial nor in the extended poststopping phases of the study [2].
Source: Maturitas - February 26, 2015 Category: Primary Care Authors: Faustino R. Pérez-López, Margaret Rees Source Type: research

Managing menopause.
Authors: Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W, Menopause and Osteoporosis Working Group, Fortier M, Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Graves L, Guthrie B, Khan A, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W Abstract OBJECTIVE: To provide updated guidelines for health care providers on the management of menopause in asymptomatic healthy women as well as in women presenting with vasomotor or urogenital symptoms and on considerations related to cardiovascular disease, breast cancer, urogynaecology, and sexuality. OUTCOMES: Lifestyle...
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - December 2, 2014 Category: OBGYN Tags: J Obstet Gynaecol Can Source Type: research

Pages: 1  2